President Donald Trump’s move to fire two Democrats on the Federal Trade Commission leaves a question mark over the future of an agency antitrust action alleging pharmacy benefit managers used illegal rebate programs that spiked the price of insulin.

The firings drew criticism from Democratic senators concerned that the move was designed to remove opposition within the agency to big corporations.

Removing two Democratic commissioners could trigger a cascade of problems for the longstanding agency, and even blow back on Republicans.